Literature DB >> 8103781

Dopaminergic resistance in a case of invasive macroprolactinoma.

D Schwarzstein1, A García-Patterson, G Giménez, J Calaf, M Puig-Domingo, A Caixàs, X Matías-Guiu, S M Webb.   

Abstract

Invasive prolactinoma is a relatively infrequent variety of macroprolactinoma characterized by a fast and aggressive growth, with infiltration to adjacent structures, and whose management is frequently difficult. We present the case of a fatal invasive macroprolactinoma in whom resistance to different dopaminergic drugs developed.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8103781     DOI： 10.1007/BF03348879

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  23 in total

1.  Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas.

Authors:  O Serri; H Beauregard; J Lesage; L Pedneault; R Comtois; N Jilwan; M Somma; L Vachon; J Brownell
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

2.  Cerebellar metastasis from a prolactinoma during treatment with bromocriptine.

Authors:  N A Martin; M Hales; C B Wilson
Journal:  J Neurosurg       Date:  1981-10       Impact factor: 5.115

3.  The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.

Authors:  A J van der Lely; J Brownell; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1991-05       Impact factor: 5.958

4.  CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion.

Authors:  C Rasmussen; T Bergh; L Wide; J Brownell
Journal:  Clin Endocrinol (Oxf)       Date:  1987-03       Impact factor: 3.478

5.  Size reduction of macroprolactinomas by bromocriptine or lisuride treatment.

Authors:  P Chiodini; A Liuzzi; R Cozzi; G Verde; G Oppizzi; D Dallabonzana; B Spelta; F Silvestrini; G Borghi; G Luccarelli; E Rainer; R Horowski
Journal:  J Clin Endocrinol Metab       Date:  1981-10       Impact factor: 5.958

Review 6.  Malignant prolactinomas.

Authors:  E A Popovic; J R Vattuone; K H Siu; I Busmanis; M J Pullar; J Dowling
Journal:  Neurosurgery       Date:  1991-07       Impact factor: 4.654

7.  CV205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man.

Authors:  P S Barnett; J M Dawson; J Butler; P B Coskeran; J J Maccabe; A M McGregor
Journal:  Clin Endocrinol (Oxf)       Date:  1990-08       Impact factor: 3.478

8.  Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.

Authors:  J W van't Verlaat; R J Croughs; J Brownell
Journal:  Clin Endocrinol (Oxf)       Date:  1990-11       Impact factor: 3.478

9.  CV 205-502 treatment of hyperprolactinemia.

Authors:  M L Vance; J R Cragun; C Reimnitz; R J Chang; E Rashef; R E Blackwell; M M Miller; M E Molitch
Journal:  J Clin Endocrinol Metab       Date:  1989-02       Impact factor: 5.958

10.  Prolactin cell carcinoma of the pituitary. Clinicopathologic, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases.

Authors:  B W Scheithauer; R V Randall; E R Laws; K T Kovacs; E Horvath; M D Whitaker
Journal:  Cancer       Date:  1985-02-01       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.